Iveric Bio Inc Stock Price, News & Analysis

Iveric Bio reported its fourth quarter and full year 2021 results, highlighting strong progress in the GATHER2 trial for Zimura®, a treatment for geographic atrophy (GA). The trial maintains a patient retention rate exceeding 90%, with 84% completion for year one. The company is preparing for an NDA filing and plans to initiate a Phase 3 trial for intermediate AMD in late 2022. Financially, Iveric recorded a net loss of $33 million in Q4 2021, totaling $114.5 million for the year. The company holds approximately $381.7 million in cash, forecasting sufficient funds through mid-2024.

Iveric Bio (Nasdaq: ISEE) will announce its Q4 and full year 2021 financial results on February 24, 2022, followed by a conference call at 8:00 a.m. ET. The company focuses on developing treatments for retinal diseases, especially targeting age-related macular degeneration. Investors can join the call by dialing 1-888-317-6003 (USA) or 1-412-317-6061 (International) with passcode 8865993. A replay will be available for two weeks.

Iveric Bio (ISEE) announced the results of a post-hoc analysis from its Phase 3 GATHER1 clinical trial for Zimura, focusing on Geographic Atrophy (GA) progression. This analysis demonstrated a significant reduction in lesion growth in patients receiving Zimura 2 mg compared to a sham group over 18 months. The results suggest that Zimura may help preserve central vision by slowing GA progression. The company anticipates topline data from the GATHER2 trial in the second half of 2022, with potential applications for regulatory approvals if results are positive.

IVERIC Bio (ISEE) announced the presentation of new post-hoc analyses from the GATHER1 Phase 3 trial for Zimura® (avacincaptad pegol) at the Angiogenesis, Exudation, and Degeneration 2022 meeting on February 11-12, 2022. The analyses aim to assess the effectiveness of Zimura in slowing Geographic Atrophy (GA) progression related to Age-related Macular Degeneration (AMD). Presenters include experts from Duke Eye Center and Cleveland Clinic. IVERIC Bio plans to release more details during the presentations and will share slides on its website.

IVERIC bio (NASDAQ: ISEE) announced on February 1, 2022, that it granted an equity-based award to a newly-hired non-executive employee. This inducement grant consists of non-statutory stock options for 14,000 shares, with an exercise price of $14.43 per share, equating to IVERIC’s closing stock price on the grant date. The options vest over four years, beginning with 25% on February 1, 2023. The award is part of IVERIC’s 2019 Inducement Stock Incentive Plan, emphasizing its commitment to attracting talent for its research in retinal diseases.

Melinta Therapeutics announced that its President and CEO, Christine Ann Miller, has joined the Board of Directors of IVERIC bio, Inc. (NASDAQ: ISEE). This move is effective immediately and aims to bolster Iveric's leadership as it prepares for the potential launch of its treatment for age-related macular degeneration. With over 20 years of experience in life sciences, Miller's prior achievements include directing over 50 product launches at Sandoz, generating over $300 million in new annual revenue. The addition is expected to strengthen Iveric's commitment to patient outcomes.

Iveric Bio announces the election of Christine Ann Miller to its Board of Directors. With over 20 years of experience in life sciences and currently serving as CEO of Melinta Therapeutics, she brings extensive expertise in global product launches and supply chain management. Miller's past achievements at Sandoz include directing over 50 product launches generating more than $300 million in revenue. CEO Glenn P. Sblendorio expressed confidence in Miller's ability to support the company's growth and upcoming Zimura launch in retinal disease treatments.

Iveric Bio (NASDAQ: ISEE) announced on January 3, 2022, the grant of equity-based awards to eight newly-hired non-executive employees. The inducement grants consist of 178,000 non-statutory stock options and 6,500 restricted stock units. The stock options have an exercise price of $16.57, equal to Iveric's closing stock price on the grant date, and vest over four years. The grants are intended to attract talent and align employee compensation with the company's performance, reflecting Iveric's commitment to developing treatments for retinal diseases.

Iveric Bio (Nasdaq: ISEE) has announced that Dr. Pravin U. Dugel, President, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The presentation will be available starting January 10 at 7:00 a.m. ET, accessible via the Investor section on the Iveric Bio website. An archived replay will be available for 30 days. Iveric Bio focuses on developing treatments for retinal diseases, particularly age-related macular degeneration.